我国自主研制的SARS灭活疫苗Ⅰ期临床试验已经顺利完成,取得了阶段性的重大进展。36位受试者均未出现异常反应,其中24位接种疫苗的受试者全部产生了抗体,表明我国自主研制的疫苗是安全的,初步证明是有效的。科技部、卫生部、国家食品药品监督管理局今天为此共同组织了SARS疫苗Ⅰ期临床研究结果 China’s self-developed SARS inactivated vaccine phase Ⅰ clinical trials have been successfully completed, and made significant progress in stages. Thirty-six subjects had no abnormal reaction, of which 24 vaccinated subjects all produced antibodies, indicating that our self-developed vaccine is safe and initially proved to be effective. Ministry of Science and Technology, Ministry of Health and State Food and Drug Administration jointly organized the Phase I clinical trial on SARS vaccine today